US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder.

Ads

You May Also Like

Immuron Reports Positive Results in NASH Clinical Trial

Headlines: First-In Class Anti-LPS Mechanism of Action confirmed for IMM-124EResults demonstrate excellent safety and ...